Medicus Pharma (MDCX) COO granted 50,000 options at $0.50 exercise price

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported that Chief Operating Officer Smith Andrew Alasdair received a compensation grant of stock options. The award covers 50,000 options, each giving the right to buy one common share at an exercise price of $0.50 per share. The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, he holds 50,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Smith Andrew Alasdair

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 50,000 options Exercise price: $0.50 per share Total options after grant: 50,000 options +2 more

5 metrics

Options granted 50,000 options Stock Option (right to buy) grant to COO

Exercise price $0.50 per share Conversion or exercise price of granted options

Total options after grant 50,000 options Total derivative holdings following this transaction

Exercise date March 26, 2027 Date options become exercisable

Expiration date March 27, 2031 Date granted options expire

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Shares, exercise price

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

exercise price financial

"conversion_or_exercise_price: "0.5000" as the exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Andrew Alasdair

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		50,000		03/26/2027	03/27/2031	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Andrew A. Smith	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Medicus Pharma (MDCX) disclose in this Form 4 filing?

Medicus Pharma disclosed that COO Smith Andrew Alasdair received a grant of 50,000 stock options as compensation. These options allow him to buy common shares at a fixed price of $0.50, starting March 26, 2027, and expiring March 27, 2031.

How many stock options did the Medicus Pharma (MDCX) COO receive?

The COO received 50,000 stock options in this transaction. Each option represents the right to purchase one common share at a set exercise price of $0.50, providing potential value if the market price later exceeds that level before expiration.

What is the exercise price of the Medicus Pharma (MDCX) stock options granted?

The stock options were granted with an exercise price of $0.50 per common share. This means the COO can buy shares at $0.50 once the options become exercisable, potentially benefiting if the trading price is higher at exercise time.

When do the new Medicus Pharma (MDCX) options become exercisable and when do they expire?

The options become exercisable on March 26, 2027, and expire on March 27, 2031. Between those dates, the COO can choose to exercise the options at $0.50 per share, provided other plan conditions are satisfied.

Is this Medicus Pharma (MDCX) Form 4 an open-market stock purchase or sale?

No, this Form 4 reports a compensation grant, not an open-market trade. The COO received 50,000 stock options at a $0.50 exercise price, classified as a grant or award acquisition rather than buying or selling shares in the market.

How many Medicus Pharma (MDCX) options does the COO hold after this grant?

After the grant, the COO holds 50,000 stock options directly. The filing shows this entire amount comes from the reported award, with no additional derivative positions listed in the derivative holdings summary for this insider.